摘要
目的评价紫杉醇脂质体联合卡铂在三阴性乳腺癌新辅助化疗的临床疗效和不良反应。方法确诊的34例三阴性乳腺癌患者采用紫杉醇脂质体+卡铂方案进行新辅助化疗,紫杉醇脂质体135 mg/m2+卡铂(AUC=6),21 d为1个周期,每位患者取前4周期,紫杉醇脂质体给药前未进行任何预处理。结果 34例均可评价疗效,临床完全缓解为26.5%,临床部分缓解为50%,临床有效率为76.5%,其中病理完全缓解为20.6%。主要不良反应为骨髓抑制、肝功能异常及脱发,多为Ⅰ～Ⅱ度,其发生率分别为61.8%、35.3%和32.4%,无明显超敏反应,无治疗相关性死亡。结论紫杉醇脂质体联合卡铂方案在三阴性乳腺癌新辅助化疗中的临床疗效好,毒副反应少,患者耐受性好。
Objective To evaluate clinic curative effect and adverse reaction of neoadjuvant chemotherapy in triple negative breast cancer with paclitaxel liposome and carboplatin. Methods 34 Cases breast cancer had accepted neoadjuvant chemotherapy with paclitaxel liposome 135 mgc/m^2 and carboplatin AUC = 6, every patient accept four cycles at least and one timing is 3 weeks. Pretreatment was not used before and after paclitaxel liposome. Results All patients were evaluable,9 eases（26. 5% ） were CR,17 cases（50% ） were PR,tohal effective rate were 76. 5% ,and 7 cases（20.6% ） were pCR. The main adverse reaction in- clude marrow suppression, abnormal results of liver function studies and alopecia, the incidence rate were 61.8% , 35.3 % and 32.4% respectively, most of side effects were grade Ⅰ～Ⅱ. There are no serious hypersensitivity and death during treatment. Conclusion Clinic curative effect and adverse reaction of neoadjurant chemotherapy in breast cancer with paclitaxel liposome and carboplatin was better and adverse reaction were fewer. Tolerance of breast cancer patients is better
出处
《中国肿瘤临床与康复》
2011年第6期549-551,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
紫杉醇脂质体
卡铂
乳腺肿瘤
新辅助化疗
Paclitaxel liposome
Carboplatin
Breast neoplasms
Neoadjuvant chemotherapy
作者简介
王剑，男，主治医师，从事乳腺疾病的诊断及治疗专业。
